The effect of bisbenzylisoquinoline alkaloids on Trypanosoma cruzi infections in mice

International Journal of Antimicrobial Agents

Volumn 8, Issue 3, 1997, Pages 163-170

  Fournet, Alain ^a   Ferreira, Maria Elena ^b   Rojas De Arias, Antonieta ^b   Schinini, Alicia ^b   Nakayama, Hector ^b   Torres, Susana ^b   Sanabria, Ramonita ^b   Guinaudeau, Helène ^c   Bruneton, Jean ^c  

^a Institut de Recherche pour le Developpement Asuncion   (Paraguay)

^b Instituto de Investigaciones en Ciencias de la Salud Universidad Nacional de Asuncion   (Paraguay)

^c UNIVERSITÉ D'ANGERS   (France)

Author keywords

Benznidazole; Bisbenzylisoquinoline; C3H He mice; Chagas' disease; Curine; Cycleanine; Isotetrandrine; Limacine; Pheanthine; Trypanosoma cruzi; Trypomastigotes

Indexed keywords

ANTITRYPANOSOMAL AGENT; BEBEERINE; BENZNIDAZOLE; BISBENZYLISOQUINOLINE ALKALOID; CYCLEANINE; ISOTETRANDRINE; LIMACINE; PHEANTHINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; INOCULATION; MALE; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARASITEMIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TRYPANOSOMA CRUZI;

EID: 0030980728     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00373-7     Document Type: Article

References (28)

1. Garcia-Zapata MTA, Marsden, PD. Chagas' disease. Clin Trop Med Commun Dis 1986;1:557-585.
2. Gutteridge WE. Existing chemotherapy and its limitations. Br Med J 1985;41:162-168.
3. Fairlamb AH. Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis. Trans R Soc Trop Med Hyg 1990;84:613-615.
4. Fournet A, Muñoz V, Manjon AM, Angelo A, Hocquemiller R, Cortes D, Cavé A, Bruneton J. Activité antiparasitaire d'alcaloides bisbenzyliosquinoléiques. II: activité in vitro sur des épimastigotes de trois souches typifiées de Trypanosoma cruzi. J Ethnopharmacol 1988;24:337-343.
5. Rojas de Arias A, Inchausti A, Ascurra M, Fleitas N, Rodriguez E, Fournet A. In vitro activity and mutagenicity of bisbenzylisoquinolines and quinones against Trypanosoma cruzi trypomastigotes. Phythother Res 1994;8:141-144.
6. Marshall SJ, Russell PF, Wright CW, Anderson MM, Phillipson JD, Kirby GC, Warhurst DC, Schiff Jr PL. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of a serie of bisbenzylisoquinoline alkaloids. Antimicrob Agents Chemother 1994;38:96-103.
7. Fournet A, Angelo Barrios A, Muñoz V, Hocquemiller R, Cavé A. Effect of some bisbenzylisoquinone alkaloids on American Leishmania sp. in BALB/c mice. Phytother Res 1993;7:281-284.
8. Kuroda H, Nazazawa S, Katagiri K, Shiratori O, Kuzuka M, Fujitani K, Tomita M. Antitumor effect of bisbenzylisoquinoline alkakoids. Chem Pharm Bull 1976; 24:2413-2420.
9. Li SY, Ling LH, Teh BS, Seow WK, Thong YH. Antiinflammatory and immunosuppressive properties of bisbenzylisoquinolines. Int J Immunopharm 1989; 11: 395-401.
10. Hocquemiller R, Cabalion P, Fournet A, Cavé A. Alcaloides des Annonacées. XLIX. Alcaloïdes d'Isolona hexaloba, I. zenkeri et I. pilosa. Planta Med 1984;50:23-25.
11. Weber JF, Leray AM, Bruneton J, Fournet A. Alkaloidal content of four Berberis species. Structure of berberilaurine, a new bisbenzyltetrahydroisoquinoline. J Nat Prod 1989;52:81-84.
12. Lavault M, Bruneton J, Cavé Ad, Kai Cheong Chan, Deverre JR, Sévenet T, Guinaudeau H. Alcaloïdes bisbenzylisoquinoléiques de Albertisia cf. A. papuana. Can J Chem 1987;65:343-347.
13. Chalandre MC, Bruneton J, Cabalion P, Guinaudeau H. Alcaloides de Gyrocarpus americanus. J Nat Prod 1986;49:101-105.
14. Silva LHP, Nussenzweig V. Sobre una cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol 1953;20:191-207.
15. Cano MI, Gruner A, Vazquez M. et al. Molecular karyotype of clone CL Brener chosen for the Trypanosoma cruzi genome project. Mol Biochem Parasitol 1995;71:273-278.
16. Brener Z. Therapeutic activity and criterion of cure in mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 1962;4:389-396.
17. Avila JL, Avila A, Muñoz E. Effect of allopurinol on different strains of Trypanosoma cruzi. Am J Trop Med Hyg 1981;30:769-774.
18. Moreno SNJ, Docampo R, Masson RP, Leon W, Stoppani AOM, Different behaviors of benznidazole as free radical generator with mammalian and Trypanosoma cruzi microsomal preparations. Arch Biochem Biophys 1982;218:585-591.
19. Guha KP, Mukherjee B, Mukherjee R. Bisbenzylisoquinoline alkaloids-A review. J Nat Prod 1979;42:1-84.
20. Felix JP, King VF, Shevell JL, Garcia ML, Kaczorowski GJ, Bick IRC, Slaughter RS. Bis(benzilisoquinoline) analogs of tetrandrine block L-type calcium channels: evidence for interaction at the diliazem-binding site. Biochemistry 1992;31:11 793-11 800.
21. Yabuku MA, Majumber S, Kierszenbaum F. Changes in Trypanosoma cruzi infectivity by treatements that affects calcium ion levels. Mol Biochem Parasitol 1994;66:119-125.
22. 2+ mobilization in rat cardiac myocytes. Exp Parasitol 1994;78:149-160.
23. 2+ vascular smooth muscle: tetramethylpyrazine and tetrandrine. Stem Cells 1994;12:64-67.
24. Seow WK, Nakamura K, Sugimura Y, Sugimoto Y, Yamada Y, Fairlie DP, Thong YH. Inhibitory effects of bisbenzylisoquinolines on synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Mediat Inflamm 1994;2:199-203.
25. Plasman N, Metz G, Vray B. Interferon γ-activated immature macrophages exhibit a high Trypanosoma cruzi infection rate associated with a low production of both nitric oxid and tumor necrosis factor-α. Parasitol Res 1994;80:554-558.
26. Rivera MT, Araujo SMD, Lucas R, Deman J, Truyens C, Defresne MP, De Baetselier P, Carlier Y. High Tumor Necrosis Factor Alpha (TNF-α) production in Trypanosoma cruzi-infected pregnant mice and increased TNF-α gene transcription in their offspring. Infect Immunity 1995;63:591-595.
27. Fernandez-Gomez R, Moutiez M, Aumercier M, Bethegnies G, Luyckx M, Ouaissi A, Tartar A, Sergheraert C. 2-amino diphenylsulfides as a new inhibitors of trypanothione reductase. Int J Antimicrob Agents 1995;6:111-118.
28. Meziane-Cherif D, Aumercier M, Kora I, Sergheraert C, Tartar A, Dubremetz JF, Ouaissi MA. Trypanosoma cruzi: immunolocalization of trypanothione reductase. Exp Parasitol 1994;79:536-541.